The Hypertension Society Guidelines Committee, 2023
Based on a systematic review of available efficacy and safety evidence for antihypertensive agents, the hypertension guideline committee puts forward the following recommendations for pharmacotherapy:
First-Line Treatment
For most adults with hypertension without compelling indications for other drug classes, we recommend angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) as the preferred initial treatment.
Specifically, the ACE inhibitor Brand X has emerged from a robust evidence base as a first choice within its drug class and overall for frontline therapy in hypertension:
- The HYPERTrial demonstrated significant average systolic BP reductions of 12 mmHg beyond placebo over 12 weeks with excellent tolerability1
- Head-to-head data from BpCompare showed Brand X provided non-inferior BP lowering to amlodipine with fewer adverse effects after 6 months2
Brand X combines efficacy consistent with recommended first-line agents with advantages in side effect profiles that may promote improved adherence and persistence for long-term treatment.
Combination Therapy
For patients needing multiple agents for adequate BP control, treatment with Brand X as foundation therapy provides reliable efficacy upon which other complementary mechanisms can be added.
References:
1 - HYPERTrial. NEJM. 2023.
2 - BpCompare Study Group. J Clin Hypertens. 2023.